Genetic (Primary) Dyslipidemias

Genetic (Primary) Dyslipidemias

Disorder

Genetic Defect/Mechanism

Inheritance

Prevalence

Clinical Features

Treatment

Apo C-II deficiency [a]

Apo C-II (causing functional LPL deficiency)

Recessive

< 1/1 million

Pancreatitis (in some adults), metabolic syndrome (often present)

TG: > 750 mg/dL (> 8.5 mmol/L)

Diet: Severe fat restriction with fat-soluble vitamin supplementation and medium-chain TG supplementation

Cerebrotendinous xanthomatosis [b]

Hepatic mitochondrial 27-hydroxylase defect

Blockage of bile acid synthesis and conversion of cholesterol to cholestanol, which accumulates in blood, nervous system, and other organs

Recessive

Rare

Cataracts, premature [c]* CAD, neuropathy, ataxia

Chenodeoxycholic acid

Cholesteryl ester storage disease and Wolman disease [d]

Lysosomal acid lipase deficiency

Recessive

Rare

Premature [c] CAD

Accumulation of cholesteryl esters and TG in lysosomes in the liver, spleen, and lymph nodes

Cirrhosis

Possibly statins

Enzyme replacement

Familial apo AI deficiency/mutations [e]

Apo AI

Unknown

Rare

Corneal opacities, xanthomas, premature [c] CAD (in some people)

HDL: 15–30 mg/dL (0.39–0.78 mmol/L)

Supportive care

Familial chylomicronemic syndrome (formerly LPL deficiency) [f]

LPL gene

APOC2 gene

APOA5 gene

GP1HBP1 gene

LMF1 gene

Recessive

Rare

Hypertriglyceridemia, pancreatitis, eruptive xanthomas, lipemia retinalis

TG > 1000 mg/dL (11.2 mmol/L)

Low-fat diet

Fibrates

Plasma exchange

Olezarsen

Familial combined hyperlipidemia [g]

Unknown, possibly multiple defects and mechanisms

Dominant

1/50 to 1/100

Premature[c] CAD, responsible for approximately 15% of MIs in people < 60 years

Apo B: Disproportionately elevated

TC: 250–500 mg/dL (6.5–13.0 mmol/L)

TG: 250–750 mg/dL (2.8–8.5 mmol/L)

Low-fat diet

Weight loss

Lipid-lowering medications

Familial defective apo B-100 [h]

Apo B (LDL receptor–binding region defect)

Diminished LDL clearance

Dominant

1/700

Xanthomas, arcus corneae, premature [c] CAD

TC: 250–500 mg/dL (6.5–13 mmol/L)

Low-fat diet

Lipid-lowering medications

Familial dysbetalipoproteinemia [i]

Apo E (usually e2/e2 homozygotes)

Diminished chylomicron and VLDL clearance

Recessive (more common) or dominant (less common)

1/5000

Xanthomas (especially tuberous and palmar), yellow palmar creases, premature [c] CAD

TC: 250–500 mg/dL (6.5–13.0 mmol/L)

TG: 250–500 mg/dL (2.8–5.6 mmol/L)

Low-fat diet

Lipid-lowering medications

Familial hypercholesterolemia [j]

LDL receptor defect

Diminished LDL clearance

Codominant

Heterozygotes: 1/200

Tendon xanthomas, arcus corneae, premature [c] CAD (ages 30–50), responsible for approximately 5% of MIs in people < 60 years

TC: 250–500 mg/dL (6.5–13 mmol/L)

Low-fat diet

Lipid-lowering medications

LDL apheresis (for patients who are homozygous and those who are heterozygous with severe disease)

Homozygotes: 1/250,000–1/1 million (increased among French Canadian, Christian Lebanese, and South African populations)

Planar and tendon xanthomas and tuberous xanthomas, CAD before age 18 years

TC > 500 mg/dL (> 13 mmol/L)

Low-fat diet

Lipid-lowering medications

LDL apheresis (for patients who are homozygous and those who are heterozygous with severe disease)

Liver transplantation (for homozygous patients)

Familial hypertriglyceridemia [i]

Unknown, possibly multiple defects and mechanisms

Dominant

1/500

Usually no symptoms or findings; occasionally hyperuricemia, sometimes early atherosclerosis

TG: 200–500 mg/dL (2.3–5.6 mmol/L), possibly higher depending on diet and alcohol use

Low-fat diet

Weight loss

Lipid-lowering medications

Familial LCAT deficiency [k]

LCAT gene

Recessive

Extremely rare

Corneal opacities, anemia, chronic kidney disease

HDL: < 10 mg/dL (< 0.26 mmol/L)

Fat restriction

Renal transplantation

Fisheye disease (partial LCAT deficiency)

LCAT gene

Recessive

Extremely rare

Corneal opacities

HDL: < 10 mg/dL (< 0.26 mmol/L)

Supportive care

Hepatic lipase deficiency

Hepatic lipase

Recessive

Extremely rare

Premature [c] CAD

TC: 250–1500 mg/dL (6.5–39 mmol/L)

TG: 395–8200 mg/dL (4.5–93 mmol/L)

HDL: Variable

Low-fat diet, lipid-lowering medications

PCSK9 gain of function mutations

Increased degradation of LDL receptors

Dominant

Unknown

Similar to familial hypercholesterolemia

Low-fat diet

Lipid-lowering medications

Polygenic hypercholesterolemia

Unknown, possibly multiple defects and mechanisms

Variable

Common

Premature [c] CAD

TC: 250–350 mg/dL (6.5–9.0 mmol/L)

Low-fat diet

Lipid-lowering medications

Primary hypoalphalipoproteinemia (familial or nonfamilial)

Unknown, possibly apo A-I, C-III, or A-IV

Dominant

Rare

Premature [c] CAD

HDL: 15–35 mg/dL (0.39–0.91 mmol/L)

Exercise

LDL-lowering medications

Sitosterolemia

ABCG5 and ABCG8 genes

Recessive

Rare

Tendon xanthomas, premature [c] CAD

Fat restriction

Bile acid sequestrants

Ezetimibe

Tangier disease

ABCA1 gene

Recessive

Rare

Premature [c] CAD (in some people), peripheral neuropathy, hemolytic anemia, corneal opacities, hepatosplenomegaly, orange tonsils

HDL: < 5 mg/dL (< 0.13 mmol/L)

Low-fat diet

[a] Prevalence data from Hoffmann, M.M., März, W. (2009). Apo C-II Deficiency. In: Lang, F. (eds) Encyclopedia of Molecular Mechanisms of Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-29676-8_137

[b] Prevalence data from Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 2014;9:179. Published 2014 Nov 26. doi:10.1186/s13023-014-0179-4

[c] Premature coronary artery disease occurs at < 55 years in men and < 65 years in women.

[d] Prevalence data from Pericleous M, Kelly C, Wang T, Livingstone C, Ala A. Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. Lancet Gastroenterol Hepatol 2017;2(9):670-679. doi:10.1016/S2468-1253(17)30052-3

[e] Data from Geller AS, Polisecki EY, Diffenderfer MR, et al. Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. J Lipid Res 2018;59(12):2421-2435. doi:10.1194/jlr.M088203

[f] Prevalence data from Javed F, Hegele RA, Garg A, et al. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. J Clin Lipidol published March 21, 2025. doi: 10.1016/j.jacl.2025.03.013

[g] Prevalence data from Taghizadeh E, Farahani N, Mardani R, Taheri F, Taghizadeh H, Gheibihayat SM. Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update. Biochem Genet 2022;60(2):453-481. doi:10.1007/s10528-021-10130-2

[h] Prevalence data from Tybjaerg-Hansen A, Humphries SEAtherosclerosis. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease.  1992;96(2-3):91-107. doi:10.1016/0021-9150(92)90056-m

[i] Data from Shah AS, Wilson DP. Genetic Disorders Causing Hypertriglyceridemia in Children and Adolescents. [Updated 2023 Feb 22]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395571/

[j] Data from Jackson CL, Ahmad Z, Das SR, Khera A. The evaluation and management of patients with LDL-C ≥ 190 ​mg/dL in a large health care system. Am J Prev Cardiol 2020;1:100002. Published 2020 May 1. doi:10.1016/j.ajpc.2020.100002

[k] Data from Mehta R, Elias-Lopez D, Martagon AJ, et al. LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred. Lipids Health Dis 2021;20(1):70. Published 2021 Jul 13. doi:10.1186/s12944-021-01498-6

ABCA1 =adenosine triphosphate (ATP)-binding cassette transporter A1; ABCG5 and 8 = ATP-binding cassette subfamily G members 5 and 8; apo = apoprotein; CAD = coronary artery disease; HDL = high-density lipoprotein; LCAT =lecithin-cholesterol acyltransferase; LDL = low-density lipoprotein; LPL = lipoprotein lipase; MI = myocardial infarction; PCSK9 = proprotein convertase subtilisin-like/kexin type 9; TC = total cholesterol; TG = triglyceride; VLDL = very-low-density lipoprotein.

[a] Prevalence data from Hoffmann, M.M., März, W. (2009). Apo C-II Deficiency. In: Lang, F. (eds) Encyclopedia of Molecular Mechanisms of Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-29676-8_137

[b] Prevalence data from Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 2014;9:179. Published 2014 Nov 26. doi:10.1186/s13023-014-0179-4

[c] Premature coronary artery disease occurs at < 55 years in men and < 65 years in women.

[d] Prevalence data from Pericleous M, Kelly C, Wang T, Livingstone C, Ala A. Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. Lancet Gastroenterol Hepatol 2017;2(9):670-679. doi:10.1016/S2468-1253(17)30052-3

[e] Data from Geller AS, Polisecki EY, Diffenderfer MR, et al. Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. J Lipid Res 2018;59(12):2421-2435. doi:10.1194/jlr.M088203

[f] Prevalence data from Javed F, Hegele RA, Garg A, et al. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. J Clin Lipidol published March 21, 2025. doi: 10.1016/j.jacl.2025.03.013

[g] Prevalence data from Taghizadeh E, Farahani N, Mardani R, Taheri F, Taghizadeh H, Gheibihayat SM. Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update. Biochem Genet 2022;60(2):453-481. doi:10.1007/s10528-021-10130-2

[h] Prevalence data from Tybjaerg-Hansen A, Humphries SEAtherosclerosis. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease.  1992;96(2-3):91-107. doi:10.1016/0021-9150(92)90056-m

[i] Data from Shah AS, Wilson DP. Genetic Disorders Causing Hypertriglyceridemia in Children and Adolescents. [Updated 2023 Feb 22]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395571/

[j] Data from Jackson CL, Ahmad Z, Das SR, Khera A. The evaluation and management of patients with LDL-C ≥ 190 ​mg/dL in a large health care system. Am J Prev Cardiol 2020;1:100002. Published 2020 May 1. doi:10.1016/j.ajpc.2020.100002

[k] Data from Mehta R, Elias-Lopez D, Martagon AJ, et al. LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred. Lipids Health Dis 2021;20(1):70. Published 2021 Jul 13. doi:10.1186/s12944-021-01498-6

ABCA1 =adenosine triphosphate (ATP)-binding cassette transporter A1; ABCG5 and 8 = ATP-binding cassette subfamily G members 5 and 8; apo = apoprotein; CAD = coronary artery disease; HDL = high-density lipoprotein; LCAT =lecithin-cholesterol acyltransferase; LDL = low-density lipoprotein; LPL = lipoprotein lipase; MI = myocardial infarction; PCSK9 = proprotein convertase subtilisin-like/kexin type 9; TC = total cholesterol; TG = triglyceride; VLDL = very-low-density lipoprotein.

In these topics